Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.

A study to evaluate the efficacy of lenalidomide as maintenance therapy after completion of first-line combination chemotherapy in patients with mantle cell lymphoma (MCL) who are not candidates for transplantation and have achieved partial response (PR) or complete response (CR).

This study was prematurely terminated by the sponsor in light of new unpublished data that rendered the current design of the study no longer clinically relevant. A study design with the control arm of no active treatment was no longer appropriate. The termination of the trial was not based on any safety concerns in the study.

Inclusion Criteria:

• Histologically-proven mantle cell non-Hodgkin's lymphoma,
• One of the following first-line induction chemotherapy regimens with rituximab: (1) combination regimen containing all of the following components: cyclophosphamide, vincristine, adriamycin and a glucocorticoid; (2) Fludarabine containing regimen such as FC (fludarabine, cyclophosphamide)
• Achieved a PR or better response after the first-line induction chemotherapy regimen (assessed by 2007 Revised Response Criteria for Malignant Lymphoma)
• ECOG performance status score of ≤ 2
• Willing to follow pregnancy precaution

Exclusion Criteria:

• Patients who have received more than 1 line of induction chemotherapy;
• Patients who have received less than 4 cycles of R-CHOP, R-CHOP-like, or R-FC are ineligible;
• Patients who achieved stable disease or progressive disease as best response with first line-induction chemotherapy;
• Any of the following laboratory abnormalities:
• Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5*10^9/L)
• Platelet count < 60,000/mm^3 (60*10^9/L)
• Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT)) > 3.0 times upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma
• Serum bilirubin > 1.5 times ULN, except in case of Gilbert's Syndrome and documented liver involvement by lymphoma
• Calculated creatinine clearance (i.e. Cockcroft-Gault formula) of < 30 mL /min
• Active or any history of central nervous system (CNS) lymphoma or leptomeningeal involvement by lymphoma
• Subjects at high risk for deep vein thrombosis (DVT) not willing to take DVT prophylaxis
• Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)

• Multicenter publication must include input from investigators and Celgene, agreement to be established before publication.
• Multicenter publication has priority over subset (single center) publication, for duration of 1 year after study completion.
• Individual investigators have publication right after multicenter publication is complete or 1 year after study completion, whichever is first. Celgene has the right to comment and right to ask delay of publication for up to 90 days.